Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
2.
J Clin Endocrinol Metab ; 108(12): e1580-e1587, 2023 Nov 17.
Article in English | MEDLINE | ID: mdl-37339320

ABSTRACT

CONTEXT: The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. OBJECTIVE: This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). METHODS: We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort. RESULTS: MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged ≥16 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07). CONCLUSION: We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.


Subject(s)
Hypogonadism , Puberty, Delayed , Adolescent , Humans , Female , Animals , Mice , Receptor, Melanocortin, Type 3 , Prevalence , Hypogonadism/epidemiology , Hypogonadism/genetics , Hypogonadism/complications , Puberty, Delayed/epidemiology , Puberty, Delayed/genetics , Puberty, Delayed/diagnosis , Puberty/genetics , Growth Disorders/genetics
3.
Lancet Diabetes Endocrinol ; 11(3): 203-216, 2023 03.
Article in English | MEDLINE | ID: mdl-36620967

ABSTRACT

Puberty is a major maturational event; its mechanisms and timing are driven by genetic determinants, but also controlled by endogenous and environmental cues. Substantial progress towards elucidation of the neuroendocrine networks governing puberty has taken place. However, key aspects of the mechanisms responsible for the precise timing of puberty and its alterations have only recently begun to be deciphered, propelled by epidemiological data suggesting that pubertal timing is changing in humans, via mechanisms that are not yet understood. By integrating basic and clinical data, we provide a comprehensive overview of current advances on the physiological basis of puberty, with a particular focus on the roles of kisspeptins and other central transmitters, the underlying molecular and endocrine mechanisms, and the pathways involved in pubertal modulation by nutritional and metabolic cues. Additionally, we have summarised molecular features of precocious and delayed puberty in both sexes, as revealed by clinical and genetic studies. This Review is a synoptic up-to-date view of how puberty is controlled and of the pathogenesis of major pubertal alterations, from both a clinical and translational perspective. We also highlight unsolved challenges that will seemingly concentrate future research efforts in this active domain of endocrinology.


Subject(s)
Puberty, Precocious , Puberty , Male , Female , Humans , Kisspeptins/genetics , Kisspeptins/metabolism , Puberty, Precocious/genetics
5.
J Neuroendocrinol ; 34(2): e12979, 2022 02.
Article in English | MEDLINE | ID: mdl-33904190

ABSTRACT

Puberty is a crucial biological process normally occurring at a specific time during the lifespan, during which sexual and somatic maturation are completed, and reproductive capacity is reached. Pubertal timing is not only determined by genetics, but also by endogenous and environmental cues, including nutritional and metabolic signals. During the last decade, we have learned much regarding the essential roles of kisspeptins and the neuropeptide pathways that converge on these neurones to modulate kisspeptin signalling, as well as neurokinin B and dynorphin, the co-transmitters of Kiss1 neurones in the arcuate nucleus, and the effects of melanocortins on puberty. Indeed, melanocortins are involved in transmitting the regulatory actions of metabolic cues on pubertal maturation. Intracellular metabolic sensors, such as the AMP-activated protein kinase and the fuel-sensing deacetylase SIRT1, have been shown to contribute to puberty. Further understanding of these signals and regulatory circuits will help uncover the intimacies of the central control of puberty, as well as how alterations in metabolic status, ranging from undernutrition to obesity, affect the pubertal process. Precocious puberty is rare and has a clear female predominance. Central precocious puberty (CPP) is diagnosed when premature activation of the hypothalamic-pituitary axis occurs. Its causes are heterogeneous, with alterations of the central nervous system being of special interest, and with environmental factors also playing a role in some cases. During the last decade, several mutations in different genes (including KISS1, KISS1R, MKRN3 and DLK1) that cause CPP have been discovered. Loss-of-function mutations in MKRN3 are the most common monogenic cause of CPP known to date. Here, we review and update what is known regarding the genotype-phenotype relationship in patients with CPP.


Subject(s)
Puberty, Precocious , Female , Humans , Kisspeptins/metabolism , Male , Melanocortins , Puberty, Precocious/genetics , Receptors, Kisspeptin-1/genetics , Sexual Maturation/physiology , Ubiquitin-Protein Ligases
6.
J Pediatr Endocrinol Metab ; 34(11): 1371-1377, 2021 Nov 25.
Article in English | MEDLINE | ID: mdl-34298591

ABSTRACT

OBJECTIVES: Longer-acting gonadotropin-releasing hormone analogs (GnRHa) have been widely used for central precocious puberty (CPP) treatment. However, the follow-up of patients after this treatment are still scarce. Our aim was to describe anthropometric, metabolic, and reproductive follow-up of CPP patients after treatment with leuprorelin acetate 3-month depot (11.25 mg). METHODS: Twenty-two female patients with idiopathic CPP were treated with leuprorelin acetate 3-month depot (11.25 mg). Their medical records were retrospectively evaluated regarding clinical, hormonal, and imaging aspects before, during, and after GnRHa treatment until adult height (AH). RESULTS: At the diagnosis of CPP, the mean chronological age (CA) was 8.2 ± 1.13 year, and mean bone age (BA) was 10.4 ± 1.4 year. Mean height SDS at the start and the end of GnRHa treatment was 1.6 ± 0.8 and 1.3 ± 0.9, respectively. The mean duration of GnRHa treatment was 2.8 ± 0.8 year. Mean predicted adult heights (PAH) at the start and the end of GnRH treatment was 153.2 ± 8.6 and 164.4 ± 7.3 cm, respectively (p<0.05). The mean AH was 163.2 ± 6.2 cm (mean SDS: 0.1 ± 1). All patients were within their target height (TH) range. There was a decrease in the percentage of overweight and obesity from the diagnosis until AH (39-19% p>0.05). At the AH, the insulin resistance and high LDL levels were identified in 3/17 patients (17.6%) and 2/21 patients (9.5%), respectively. The mean CA of menarche was 12.2 ± 0.5 years. At the AH, PCOS was diagnosed in one patient (4.8%). CONCLUSIONS: Long-term anthropometric, metabolic, and reproductive follow-up of patients with CPP treated with longer-acting GnRHa revealed effectivity, safety, and favorable outcomes.


Subject(s)
Body Height/drug effects , Gonadotropin-Releasing Hormone/analogs & derivatives , Leuprolide/therapeutic use , Menarche/drug effects , Puberty, Precocious/drug therapy , Reproduction/drug effects , Child , Female , Humans , Leuprolide/administration & dosage , Puberty, Precocious/mortality , Retrospective Studies , Treatment Outcome
7.
PLoS Biol ; 17(11): e3000532, 2019 11.
Article in English | MEDLINE | ID: mdl-31697675

ABSTRACT

Mkrn3, the maternally imprinted gene encoding the makorin RING-finger protein-3, has recently emerged as putative pubertal repressor, as evidenced by central precocity caused by MKRN3 mutations in humans; yet, the molecular underpinnings of this key regulatory action remain largely unexplored. We report herein that the microRNA, miR-30, with three binding sites in a highly conserved region of its 3' UTR, operates as repressor of Mkrn3 to control pubertal onset. Hypothalamic miR-30b expression increased, while Mkrn3 mRNA and protein content decreased, during rat postnatal maturation. Neonatal estrogen exposure, causing pubertal alterations, enhanced hypothalamic Mkrn3 and suppressed miR-30b expression in female rats. Functional in vitro analyses demonstrated a strong repressive action of miR-30b on Mkrn3 3' UTR. Moreover, central infusion during the juvenile period of target site blockers, tailored to prevent miR-30 binding to Mkrn3 3' UTR, reversed the prepubertal down-regulation of hypothalamic Mkrn3 protein and delayed female puberty. Collectively, our data unveil a novel hypothalamic miRNA pathway, involving miR-30, with a prominent role in the control of puberty via Mkrn3 repression. These findings expand our current understanding of the molecular basis of puberty and its disease states.


Subject(s)
Hypothalamus/metabolism , MicroRNAs/physiology , Sexual Maturation/genetics , Ubiquitin-Protein Ligases/genetics , Animals , Binding Sites , Cell Line , Female , Gene Expression Regulation, Developmental , Male , MicroRNAs/metabolism , Rats , Sequence Analysis, DNA
8.
Cells ; 8(4)2019 04 05.
Article in English | MEDLINE | ID: mdl-30959822

ABSTRACT

The vitamin D receptor (VDR) mediates vitamin D actions beyond bone health. While VDR activation by 1,25-dihydroxyvitamin D (1,25D) leads to robust transcriptional regulation, less is known about VDR actions in the absence of 1,25D. We analyzed the transcriptomic response to 1,25D in fibroblasts bearing a severe homozygous hereditary vitamin D resistant rickets-related p.Arg30* VDR mutation (MUT) and in control fibroblasts (CO). Roughly 4.5% of the transcriptome was regulated by 1,25D in CO fibroblasts, while MUT cells without a functional VDR were insensitive to 1,25D. Novel VDR target genes identified in human fibroblasts included bone and cartilage factors CILP, EFNB2, and GALNT12. Vehicle-treated CO and MUT fibroblasts had strikingly different transcriptomes, suggesting basal VDR activity. Indeed, oppositional transcriptional effects in basal conditions versus after 1,25D activation were implied for a subset of target genes mostly involved with cell cycle. Cell proliferation assays corroborated this conjectured oppositional basal VDR activity, indicating that precise 1,25D dosage in target tissues might be essential for modulating vitamin D actions in human health.


Subject(s)
Fibroblasts/metabolism , Receptors, Calcitriol/genetics , Transcription, Genetic/drug effects , Transcriptome/genetics , Vitamin D/analogs & derivatives , Cell Proliferation/drug effects , Down-Regulation/drug effects , Down-Regulation/genetics , Fibroblasts/cytology , Fibroblasts/drug effects , Human Umbilical Vein Endothelial Cells/drug effects , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Molecular Sequence Annotation , Mutation/genetics , Receptors, Calcitriol/metabolism , Transcriptome/drug effects , Up-Regulation/drug effects , Up-Regulation/genetics , Vitamin D/pharmacology
9.
Neuroendocrinology ; 106(3): 203-210, 2018.
Article in English | MEDLINE | ID: mdl-28558376

ABSTRACT

BACKGROUND: Hypothalamic hamartoma (HH) represents the commonest cause of organic central precocious puberty (CPP). Follow-up of these patients in adulthood is scarce. OBJECTIVE: To describe the anthropometric, metabolic, and reproductive parameters of patients with CPP due to HH before and after treatment with gonadotropin-releasing hormone analog (GnRHa). METHODS: We performed a retrospective and cross-sectional study in a single tertiary center including 14 patients (7 females) with CPP due to HH. RESULTS: The mean duration of GnRHa treatment was 7.7 ± 2.4 years in boys and 7.9 ± 2.1 years in girls. GnRHa treatment was interrupted at the mean chronological age (CA) of 12.1 ± 1.1 years in boys and 10.7 ± 0.5 years in girls. At the last visit, the mean CA of the male and female patients was 21.5 ± 3.2 and 24 ± 3.9 years, respectively. Eleven of the 14 patients reached normal final height (FH) (standard deviation score -0.6 ± 0.9 for males and -0.6 ± 0.5 for females), all of them within the target height (TH) range. The remaining 3 patients had predicted height within the TH range. The mean body mass index and the percentage of body fat mass was significantly higher in females, with a higher prevalence of metabolic disorders. All patients presented normal gonadal function in adulthood, and 3 males fathered a child. CONCLUSION: All patients with CPP due to HH reached normal FH or near-FH. A higher prevalence of overweight/obesity and hypercholesterolemia was observed in the female patients. Finally, no reproductive disorder was identified in both sexes, indicating that HH per se has no deleterious effect on the gonadotropic axis in adulthood.


Subject(s)
Gonadotropin-Releasing Hormone/analogs & derivatives , Hamartoma/complications , Hypothalamic Diseases/complications , Puberty, Precocious/drug therapy , Puberty, Precocious/etiology , Adiposity/drug effects , Body Height/drug effects , Body Mass Index , Cross-Sectional Studies , Female , Gonadotropin-Releasing Hormone/therapeutic use , Hamartoma/drug therapy , Hamartoma/physiopathology , Humans , Hypothalamic Diseases/drug therapy , Hypothalamic Diseases/physiopathology , Longitudinal Studies , Male , Puberty, Precocious/physiopathology , Reproduction/drug effects , Retrospective Studies , Treatment Outcome , Young Adult
10.
J Pediatr Endocrinol Metab ; 30(6): 657-662, 2017 May 24.
Article in English | MEDLINE | ID: mdl-28599388

ABSTRACT

BACKGROUND: The objective of the study was to determine the stress levels of girls with central precocious puberty (CPP) before and during treatment with a long-acting gonadotropin-releasing hormone agonist (GnRHa). METHODS: The Child Stress Scale (CSS) was used for 10 unrelated girls with CPP before and after the first year of GnRHa treatment. The CSS is divided into four subscales (physical, psychological, psychological with depressive component and psychophysiological reactions). Through a quantitative analysis, it is possible to classify stress into four stages: alarm, resistance, near-exhaustion and exhaustion. RESULTS: At diagnosis, 90% of the girls showed stress levels scores at the alarm or resistance stage on at least one subscale, mostly in terms of physical and psychological reactions. The mean total stress score was significantly higher before when compared to after GnRHa treatment (43.4±15.6 vs. 28.9±9.7; p<0.05). The mean stress scores obtained in all subscales, except the one on psychophysiological reactions, were significantly higher before GnRHa treatment. CONCLUSIONS: Higher stress levels were a common finding in girls with CPP before treatment. The significant stress level reduction after pubertal suppression reinforces the idea that sexual precocity is a stressful condition in children. The CSS might be a useful tool for psychological assessment of patients with CPP.


Subject(s)
Gonadotropin-Releasing Hormone/agonists , Puberty, Precocious/drug therapy , Puberty, Precocious/psychology , Stress, Psychological/diagnosis , Triptorelin Pamoate/therapeutic use , Adolescent , Child , Female , Humans , Luteolytic Agents/therapeutic use , Pilot Projects , Treatment Outcome
11.
J Clin Endocrinol Metab ; 99(7): E1209-16, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24712566

ABSTRACT

BACKGROUND: The sonic hedgehog (SHH) pathway plays a key role in rodent adrenal cortex development and is involved in tumorigenesis in several human tissues, but data in human adrenal glands are limited. OBJECTIVES: The objectives of the study were to analyze the involvement of the SHH pathway in human adrenal development and tumorigenesis and the effects of SHH inhibition on an adrenocortical tumor (ACT) cell line. PATIENTS AND METHODS: Expression of SHH pathway components was evaluated by immunohistochemistry in 51 normal adrenals (33 fetal) and 34 ACTs (23 pediatric) and by quantitative PCR in 81 ACTs (61 pediatric) and 19 controls (10 pediatric). The effects of SHH pathway inhibition on gene expression and cell viability in the NCI-H295A adrenocortical tumor cell line after cyclopamine treatment were analyzed. RESULTS: SHH pathway proteins were present in fetal and postnatal normal adrenals and showed distinct patterns of spatiotemporal expression throughout development. Adult adrenocortical carcinomas presented with higher expression of PTCH1, SMO, GLI3, and SUFU compared with normal adult adrenal cortices. Conversely, pediatric ACTs showed lower mRNA expression of SHH, PTCH1, SMO, GLI1, and GLI3 compared with normal pediatric adrenal cortices. In vitro treatment with cyclopamine resulted in decreased GLI3, SFRP1, and CTNNB1 mRNA expression and ß-catenin staining as well as decreased cell viability. CONCLUSIONS: The SHH pathway is active in human fetal and postnatal adrenals, up-regulated in adult adrenocortical carcinomas, and down-regulated in pediatric ACTs. SHH pathway antagonism impaired cell viability. The SHH pathway is deregulated in ACTs and might provide a new target therapy to be explored.


Subject(s)
Adrenal Cortex Neoplasms/genetics , Adrenal Cortex/embryology , Adrenal Cortex/growth & development , Adrenocortical Carcinoma/genetics , Hedgehog Proteins/genetics , Adrenal Cortex/metabolism , Adrenal Cortex Neoplasms/metabolism , Adrenocortical Carcinoma/metabolism , Adult , Case-Control Studies , Cells, Cultured , Child , Embryonic Development/genetics , Female , Gene Expression Regulation, Neoplastic , Hedgehog Proteins/metabolism , Humans , Infant, Newborn , Pregnancy , Retrospective Studies , Signal Transduction/genetics
12.
Clin Endocrinol (Oxf) ; 81(4): 503-10, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24717047

ABSTRACT

CONTEXT: The role of planar cell polarity (Wnt/PCP) and calcium-dependent (Wnt/Ca) noncanonical Wnt pathways in adrenocortical tumours (ACTs) is unknown. OBJECTIVES: To investigate the gene expression of Wnt/PCP and Wnt/Ca pathways and its association with TP53 p.R337H and CTNNB1 mutations in paediatric and adult ACTs and to correlate these findings with clinical outcome. PATIENTS: Expression of noncanonical Wnt-related genes was evaluated in 91 ACTs (66 children and 25 adults) by qPCR and the expression of beta-catenin, P53 and protein effectors of Wnt/Ca (NFAT) and Wnt/PCP (JNK) by immunohistochemistry. TP53 and CTNNB1 genes were sequenced. RESULTS: TP53 p.R337H mutation frequency was higher in children (86% vs 28%), while CTNNB1 mutation was higher in adults (32% vs 6%). Mortality was higher in adults harbouring TP53 p.R337H and in children with CTNNB1 mutations. Overexpression of WNT5A, Wnt/Ca ligand, was observed in children and adults. Overexpression of MAPK8 and underexpression of PRICKLE, Wnt/PCP mediators, were observed in paediatric but not in adult cases. Cytoplasmic/nuclear beta-catenin and P53 accumulation was observed in the majority of paediatric and adult ACTs as well as NFAT and JNK. Overexpression of MAPK8 and underexpression of PRICKLE were associated with mortality in children, while overexpression of WNT5A and underexpression of PRICKLE were associated with mortality in adults. CONCLUSIONS: In our study, TP53 p.R337H and CTNNB1 mutations correlated with poor prognosis in adults and children, respectively. We demonstrate, for the first time, the activation of Wnt/PCP and Wnt/Ca noncanonical pathway genes, and their association with poor outcome in children and adults, suggesting their putative involvement in ACTs aggressiveness.


Subject(s)
Adrenal Cortex Neoplasms/metabolism , Wnt Signaling Pathway/physiology , Adolescent , Adrenal Cortex Neoplasms/genetics , Adult , Aged , Child , Child, Preschool , Female , Humans , Immunohistochemistry , Infant , Male , Middle Aged , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Wnt Signaling Pathway/genetics , Young Adult , beta Catenin/genetics , beta Catenin/metabolism
13.
Am J Pathol ; 181(3): 1017-33, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22800756

ABSTRACT

Dysregulation of the WNT and insulin-like growth factor 2 (IGF2) signaling pathways has been implicated in sporadic and syndromic forms of adrenocortical carcinoma (ACC). Abnormal ß-catenin staining and CTNNB1 mutations are reported to be common in both adrenocortical adenoma and ACC, whereas elevated IGF2 expression is associated primarily with ACC. To better understand the contribution of these pathways in the tumorigenesis of ACC, we examined clinicopathological and molecular data and used mouse models. Evaluation of adrenal tumors from 118 adult patients demonstrated an increase in CTNNB1 mutations and abnormal ß-catenin accumulation in both adrenocortical adenoma and ACC. In ACC, these features were adversely associated with survival. Mice with stabilized ß-catenin exhibited a temporal progression of increased adrenocortical hyperplasia, with subsequent microscopic and macroscopic adenoma formation. Elevated Igf2 expression alone did not cause hyperplasia. With the combination of stabilized ß-catenin and elevated Igf2 expression, adrenal glands were larger, displayed earlier onset of hyperplasia, and developed more frequent macroscopic adenomas (as well as one carcinoma). Our results are consistent with a model in which dysregulation of one pathway may result in adrenal hyperplasia, but accumulation of a second or multiple alterations is necessary for tumorigenesis.


Subject(s)
Adrenal Cortex Neoplasms/pathology , Cell Transformation, Neoplastic/pathology , Disease Progression , Insulin-Like Growth Factor II/metabolism , beta Catenin/metabolism , Adenomatous Polyposis Coli Protein/metabolism , Adrenal Cortex Hormones/metabolism , Adrenal Cortex Neoplasms/genetics , Animals , Biomarkers, Tumor/metabolism , Cell Transformation, Neoplastic/genetics , DNA Methylation/genetics , Gene Expression Regulation, Neoplastic , Genomic Imprinting , Humans , Hyperplasia , Lymphoid Enhancer-Binding Factor 1/metabolism , Mice , Mice, Knockout , Multivariate Analysis , Mutation/genetics , Neoplasm Grading , Neoplasm Staging , Prognosis , Proportional Hazards Models , Protein Stability , Protein Transport , Up-Regulation/genetics
14.
Arq. bras. endocrinol. metab ; 49(1): 87-97, jan.-fev. 2005. ilus, tab
Article in Portuguese | LILACS | ID: lil-399050

ABSTRACT

A síndrome de insensibilidade aos andrógenos (AIS) é uma doença com herança ligada ao cromossomo X que afeta pacientes com cariótipo 46,XY, nos quais há prejuízo total (forma completa, CAIS) ou parcial (PAIS) do processo de virilização intra-útero devido à alteração funcional do receptor de andrógenos (AR). Apresentamos uma revisão da AIS e do AR com os dados clínicos, hormonais e moleculares de 33 casos. Analisamos a região codificadora do gene do AR em 33 pacientes de 21 famílias, com quadro clínico e hormonal sugestivo de AIS. Onze pacientes (9 famílias) com diagnóstico de CAIS e 22 pacientes (12 famílias) com diagnóstico de PAIS. Identificamos mutações no gene do receptor androgênico e a etiologia da síndrome de insensibilidade aos andrógenos em 86 por cento das 21 famílias estudadas: 100 por cento das famílias com insensibilidade completa aos andrógenos e 75 por cento das famílias com insensibilidade parcial aos andrógenos. Identificamos 9 mutações no AR descritas anteriormente na literatura (N705S, W741C, M742V, R752X, Y763C, R779W, M807V, R855C e R855H) e 7 mutações foram descritas pela primeira vez nesta casuística (S119X, T602P, L768V, R840S, I898F, P904R e IVS3 - 60 G>A).


Subject(s)
Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Androgen-Insensitivity Syndrome/genetics , Androgen-Insensitivity Syndrome/diagnosis , Mutation , Receptors, Androgen/genetics
15.
Arq Bras Endocrinol Metabol ; 49(1): 87-97, 2005 Feb.
Article in Portuguese | MEDLINE | ID: mdl-16544039

ABSTRACT

Androgen insensitivity syndrome (AIS) is a rare X-linked recessive condition in which patients with 46,XY karyotype have a complete (CAIS) or partial (PAIS) impairment of pre- and postnatal virilization due to mutations in the androgen receptor (AR). We present a concise revision of AIS and the AR and report the clinical, hormonal and molecular study of 33 subjects with AIS. The coding region of the AR was analyzed in 33 subjects with clinical and hormonal characteristics that suggested AIS. Eleven patients (9 families) had CAIS and 22 patients (12 families) had PAIS. Mutations in the AR were identified and the molecular diagnosis of AIS established in 100% of families with CAIS and 75% with PAIS. Nine mutations had been previously described (N705S, W741C, M742V, R752X, Y763C, R779W, M807V, R855C e R855H) and 7 mutations were first described in these cohort of patients (S119X, T602P, L768V, R840S, I898F, P904R e IVS3 - 60 G>A).


Subject(s)
Androgen-Insensitivity Syndrome/genetics , Adolescent , Adult , Androgen-Insensitivity Syndrome/diagnosis , Child , Child, Preschool , Female , Humans , Male , Mutation , Receptors, Androgen/genetics
16.
J Clin Endocrinol Metab ; 89(9): 4338-42, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15356030

ABSTRACT

Long-acting GnRH analogs represent the standard treatment for gonadotropin-dependent precocious puberty. The aim of this study was to determine the hormonal parameters for monitoring the adequacy of depot leuprolide acetate treatment in girls with clinical and hormonal diagnosis of gonadotropin-dependent precocious puberty. Eighteen girls were treated monthly with 3.75 mg depot leuprolide acetate. Adequate hypothalamic-pituitary-gonadal axis suppression during treatment was achieved in 16 of the 18 girls according to the clinical parameters and prepubertal LH levels. In these 16 well-controlled girls, the LH peak after a classical GnRH test was compared with a single LH measurement obtained 2 h after depot leuprolide acetate administration before and during GnRH analog treatment. Before therapy, the mean +/- sd LH peak after a classical GnRH test was 18.4 +/- 11.2 IU/liter (ranging from 7-41.5 IU/liter), and it was 22.6 +/- 8.3 IU/liter 2 h after the first depot leuprolide dose (ranging from 10-35.3 IU/liter). During therapy, the mean +/- sd of LH peak after classical GnRH test was 1.4 +/- 0.6 IU/liter (ranging from <0.6 to 2.3 IU/liter), and it was 2.7 +/- 1.9 IU/liter (ranging from 0.7-6.6 IU/liter) 2 h after depot leuprolide. The LH peak after a classical GnRH test and that 2 h after depot leuprolide administration correlate significantly before and during treatment. In conclusion, we established the LH cut-off values for an adequate depot leuprolide therapy as an LH peak below 2.3 IU/liter after a classical GnRH test or below 6.6 IU/liter 2 h after depot leuprolide. The latter measurement may replace the classical GnRH test as a reliable and convenient tool for monitoring therapy in female gonadotropin-dependent precocious puberty.


Subject(s)
Leuprolide/administration & dosage , Luteinizing Hormone/blood , Puberty, Precocious/drug therapy , Child , Child, Preschool , Female , Gonadotropin-Releasing Hormone/pharmacology , Humans , Infant , Puberty, Precocious/blood , Time Factors
17.
J Clin Endocrinol Metab ; 88(7): 3241-50, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12843171

ABSTRACT

Androgen insensitivity syndrome (AIS) is caused by mutations in the androgen receptor gene and is associated with a variety of phenotypes in 46,XY individuals, ranging from phenotypic women [complete form (CAIS)] to men with minor degrees of undervirilization or infertility [partial form (PAIS)]. We studied 32 subjects with male pseudohermaphroditism from 20 families (9 CAIS, 11 PAIS) with the following criteria for AIS: 46,XY karyotype, normal male basal and human chorionic gonadotropin-stimulated levels of serum testosterone and steroid precursors, gynecomastia at puberty, and, in prepubertal patients, a family history suggestive of X-linked inheritance. The entire coding region of the androgen receptor gene was analyzed, and mutations were found in all families with CAIS and in eight of 11 families with PAIS. Fifteen different mutations were identified, including five (S119X, T602P, L768V, I898F, and P904V) that have not been described previously. Detailed clinical and hormonal features were compared with genotype in 25 subjects with AIS and confirmed by mutational analysis. LH hormone levels and the LH x testosterone product were high in all postpubertal subjects with AIS. All subjects with PAIS maintained at postpubertal age the gender identity and social sex that was assigned to them in infancy, in contrast to other forms of pseudohermaphroditism.


Subject(s)
Androgen-Insensitivity Syndrome/blood , Androgen-Insensitivity Syndrome/genetics , Point Mutation , Receptors, Androgen/genetics , Adolescent , Adult , Androgen-Insensitivity Syndrome/psychology , Brazil , Child , Child, Preschool , Cohort Studies , Dihydrotestosterone/blood , Disorders of Sex Development/blood , Disorders of Sex Development/genetics , Disorders of Sex Development/psychology , Estradiol/blood , Family Health , Female , Follicle Stimulating Hormone/blood , Gender Identity , Humans , Infant , Luteinizing Hormone/blood , Male , Phenotype , Sexual Behavior , Social Behavior , Testosterone/blood
18.
J Clin Endocrinol Metab ; 87(11): 5076-84, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12414875

ABSTRACT

Pituitary stalk interruption and ectopic posterior lobe on magnetic resonance imaging (MRI) are frequently observed in patients with GH deficiency (GHD), but their pathogenesis remains controversial. We performed pituitary stimulation tests, MRI, and studied GH-1, GHRH receptor (GHRH-R), and Prophet of Pit-1 (PROP-1) genes in 76 patients with GHD. Of 33 patients with isolated GHD, 4 had GH-1 deletions and 4 had GHRH-R mutations; of 43 patients with combined pituitary hormone deficiency, 1 had PIT-1 and 5 had PROP-1 mutations. Compared with the 62 patients without mutations, 14 patients with mutations had higher frequency of consanguinity (57 vs. 2%, P < 0.001), familial cases (21 vs. 3%, P < 0.05), and lower frequency of breech delivery or hypoxemia at birth (0 vs. 39%, P < 0.005). On MRI, all patients with mutations had an intact stalk, whereas it was interrupted or thin in 74% without mutations (P < 0.001). The posterior pituitary lobe was in normal position in 92% of patients with mutations against 13% without mutations (P < 0.001). Among patients with combined pituitary hormone deficiency, hormonal deficiencies were of pituitary origin in all with PROP-1 and PIT-1 mutations and suggestive of hypothalamic origin in 81% without mutations. Perinatal insults were associated with thin/interrupted pituitary stalk, ectopic posterior lobe, and hypothalamic origin of hormonal deficiencies. In contrast, GH-1, GHRH-R, and PROP-1 mutations were associated with consanguineous parents, intact pituitary stalk, normal posterior lobe, and pituitary origin of hormonal deficiencies. We conclude that pituitary MRI and hormonal response to stimulation tests are useful in selection of patients and candidate genes to elucidate the etiological diagnosis of GHD.


Subject(s)
Homeodomain Proteins/genetics , Human Growth Hormone/deficiency , Human Growth Hormone/genetics , Mutation , Pituitary Gland/pathology , Receptors, Neuropeptide/genetics , Receptors, Pituitary Hormone-Regulating Hormone/genetics , Adolescent , Adult , Child , Child, Preschool , Consanguinity , Female , Gene Deletion , Humans , Hypothalamus/physiopathology , Infant , Magnetic Resonance Imaging , Male , Pituitary Gland/physiopathology , Pituitary Gland, Posterior/pathology
19.
Med Sci Monit ; 8(1): BR15-8, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11782667

ABSTRACT

BACKGROUND: The identification of somatic mutations in tissues is often difficult when the number of normal alleles in the tissue far exceeds the number of mutant ones. We found that the identification of gsp mutation was not possible by direct sequencing and present a new approach that improves the identification of gsp somatic mutations. MATERIAL/METHODS: Genomic DNA was extracted from frozen tissue of a human ovarian stromal Leydig cell tumor. Exons 8 and 9 of the Gsa gene were amplified by PCR and despite the abnormal migration pattern at this first DGGE, direct sequencing of the PCR product did not reveal mutations, probably due to the small amount of mutant alleles. To improve this amount, the PCR products were re-amplified using as template the excised products of the mutant homoduplex and heteroduplex bands obtained at the first DGGE. RESULTS: This approach resulted in the enhancing of the mutant homoduplex bands whereas the heteroduplex bands remained unchanged at the second DGGE. Direct sequencing of the second round PCR clearly identified the mutation R201C in the ovarian Leydig cell tumor. CONCLUSIONS: We have demonstrated a relatively rapid, convenient and reliable method to improve gsp somatic mutation detection combining a second DGGE of the PCR products obtained from the heteroduplexes and mutant homoduplex bands disclosed in a first DGGE followed by direct sequencing.


Subject(s)
GTP-Binding Protein alpha Subunits, Gs/genetics , Mutation , Nucleic Acid Heteroduplexes , Sequence Analysis, DNA , Alleles , Electrophoresis, Polyacrylamide Gel , Female , Heterozygote , Humans , Ovarian Neoplasms/metabolism , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...